The trajectory of companies tied to Sildenafil's history presents a challenging investment scenario . While the initial surge generated substantial gains, generic alternatives have significantly eroded market share . Investing in related pharmaceutical businesses now requires a thorough assessment of proprietary protection , evolving medical shifts